Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAFV600E Mutated Papillary Thyroid Cancer: Two Case Reports
Sign Up to like & getrecommendations! Published in 2017 at "Thyroid"
DOI: 10.1089/thy.2017.0106
Abstract: Background: A multi-institutional, randomized phase II trial of continuous dosing of dabrafenib with or without trametinib is ongoing in metastatic thyroid cancer. Preclinical evidence and emerging clinical experience in other cancers support evaluating intermittent dosing… read more here.
Keywords: mutated papillary; papillary thyroid; thyroid cancer; intermittent dosing ... See more keywords
Clinical response to dabrafenib plus trametinib in BRAF V600E mutated papillary craniopharyngiomas: a case report and literature review
Sign Up to like & getrecommendations! Published in 2024 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2024.1464362
Abstract: Papillary craniopharyngiomas are rare tumors prevalent to the precision oncology world due to their high rate of BRAF V600E mutations. Symptoms include vision loss, neuroendocrine dysfunction, and cognitive dysfunction. Treatment involves an interdisciplinary approach with… read more here.
Keywords: braf v600e; mutated papillary; papillary craniopharyngiomas; v600e mutated ... See more keywords